Figure 3
From: BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis
BAD and Bcl-XL binding is not required for docetaxel killing. (a) Left: MDA-MB-231 cells stably expressing vector or BAD were treated with 125 nM docetaxel for the indicated time points. Control is DMSO for 48 hours. Right: Quantification of protein band density for pBcl-XL-Ser62 over total Bcl-XL. Student’s t-test; n = 3. (b) Immunoprecipitation (IP) of BAD antibody after 24 hours of 125 nM docetaxel treatment. GST antibody was used as a negative control. (c) Immunoprecipitation with Bcl-XL antibody after 125 nM docetaxel for 5 days. Vimentin antibody was used as a negative control. Right: The flow throughs (FT) from the IPs were retained and subjected to western blot. (d) Annexin V+/PI+ staining and flow cytometry analysis of 125 nM docetaxel treated cells after 5 days. One-way ANOVA with Dunnett’s post-hoc test; n = 5.
